Immunotherapy with chemotherapy effective for rare cancers
New research has found that combining immunotherapy with chemotherapy is safe and effective for people with advanced small cell cancers in the bladder and prostate.
A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for these patients.
Small cell carcinomas can arise in various tissues – including the bladder, prostate, lung, ovaries and breast – and are known for their rapid progression, tendency to relapse after initial treatment and poor overall survival rates.
The survival time for patients with advanced small cell bladder cancer is only about seven to 13 months and only seven to nine months for patients with small cellneuroendocrine prostate cancer.
The early-stage study, published in Cell Reports Medicine, showed that using pembrolizumab with chemotherapy resulted in 43% of patients having a partial or complete regression of disease. Further, 86% of patients with bladder cancer and 57% of those with small cell/neuroendocrine prostate cancer lived for two years.
“The combination of pembrolizumab and chemotherapy presents a promising new treatment approach for these challenging-to-treat, rare cancers and could be a major breakthrough for patient care,” said Dr Arnold Chin, Professor of Urology at the David Geffen School of Medicine at UCLA and senior author of the study.
Encouraging survival rates
Immune-based treatment, such as pembrolizumab, has showed success for treating people with a variety of advanced or metastatic cancers, including patients with advanced small cell lung cancer.
Previous laboratory-based research at UCLA, led by Dr Owen Witte, Chin and colleagues, has demonstrated that small cell cancers in the bladder, lung, and prostate share many biological traits.
Building on these findings, Chin and his team designed a clinical trial involving 15 patients; seven participants with advanced or metastatic small cell bladder cancer, and eight patients with primary small cell or neuroendocrine prostate cancer.
The researchers found that patients showed favourable responses using this treatment regimen. In bladder cancer group, only one out of seven patients experienced disease progression after a median follow up of almost three years.
For the prostate cancer group, the median survival for patients with small cell/neuroendocrine prostate cancer in the trial reached 27 months, which is longer than expected compared to the historical average.
The combination treatment was also well-tolerated, with no patients needing to stop therapy due to side effects.
Along with the encouraging survival rates, the team found that the clonal expansion of CD8+ T cells in the blood in response to treatment correlated with better progression-free survival. This indicated that a blood test could be predictive of treatment response for patients in the future.
Diana Spencer, Senior Digital Content Editor, DDW
